Literature DB >> 10719821

Fibrosing cholestatic hepatitis: a report of three cases.

H K Lee1, G S Yoon, K S Min, Y W Jung, Y S Lee, D J Suh, E Yu.   

Abstract

Fibrosing cholestatic hepatitis is an aggressive and usually fatal form of viral hepatitis in immunosuppressed patients. We report three cases of fibrosing cholestatic hepatitis in various clinical situations. Case 1 was a 50-year-old man who underwent a liver transplant for hepatitis B virus (HBV)-associated liver cirrhosis. Two and a half years after the transplant, he complained of fever and jaundice, and liver enzymes were slightly elevated. Serum HBsAg was positive. Case 2 was a 30-year-old man in an immunosuppressed state after chemotherapy for acute lymphoblastic leukemia. He was a HBV carrier. Liver enzymes and total bilirubin were markedly elevated. Case 3 was a 50-year-old man who underwent renal transplantation as a known HBV carrier. One year after the transplant, jaundice developed abruptly, but liver enzymes were not significantly elevated. Microscopically lobules were markedly disarrayed, showing ballooning degeneration of hepatocytes, prominent pericellular fibrosis, and marked canalicular or intracytoplasmic cholestasis. Portal inflammation was mild, but interphase activity was definite and cholangiolar proliferation was prominent. Hepatocytes were diffusely positive for HBsAg and HBcAg in various patterns. Patients died of liver failure within 1 to 3 months after liver biopsy in spite of anti-viral treatment.

Entities:  

Mesh:

Year:  2000        PMID: 10719821      PMCID: PMC3054595          DOI: 10.3346/jkms.2000.15.1.111

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  1 in total

1.  Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer.

Authors:  Jaime Ceballos-Viro; José-M López-Picazo; José-L Pérez-Gracia; Jesús-J Sola; Gregorio Aisa; Ignacio Gil-Bazo
Journal:  World J Gastroenterol       Date:  2009-05-14       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.